The rationale for combining ADCs with checkpoint inhibitors extends beyond additive effects. Preclinical data shows ADCs can increase T-cell infiltration into the tumor, potentially turning immunologically 'cold' tumors 'hot.' This offers a promising synergistic strategy, especially for PD-L1 negative patients who typically don't respond to immunotherapy alone.

The clinical success of re-challenging patients with a different TKI after progression is not just about hitting VEGF harder. TKIs are 'dirty' drugs that also target other kinases like MET and AXL, which are present on immune cells like tumor-associated macrophages (TAMs), providing a distinct immunomodulatory effect.

An FDA analysis showed the survival curve for kidney cancer patients on IO-IO therapy (ipinevo) is much flatter for those with early tumor growth compared to IO-TKI regimens. This suggests early progression on a dual-mechanism IO-TKI therapy indicates true resistance, while on IO-IO it could be delayed response.

Successful immunotherapies like anti-PD-1 work by shifting the battlefield's arithmetic. They enhance the efficiency of each T-cell, allowing one cell to destroy five or ten cancer cells instead of three. This turns the fight into a 'numbers game' that the immune system can finally win.

Current immunocompetent mouse models for RCC have a major limitation: they are naturally T-cell depleted, with T-cells comprising only 1-10% of immune cells versus 40-70% in human tumors. This makes them excellent for studying myeloid biology but suboptimal for understanding T-cell mediated responses to immunotherapy.

The failure of the NRG trial (atezolizumab) in limited-stage SCLC suggests a negative interaction between concurrent IO and radiation. The prevailing hypothesis is that radiating the chest destroys immune cells in lymph nodes, eliminating the very T-cells crucial for the immunotherapy's mechanism of action, unlike consolidation IO which has proven effective.

While immunotherapy was a massive leap forward, Dr. Saav Solanki states the next innovation frontier is combining it with newer modalities. Antibody-drug conjugates (ADCs) and T-cell engagers are being used to recruit the immune system into the tumor microenvironment, helping patients who don't respond to current immunotherapies.

Unlike chemotherapy, neoadjuvant immunotherapy appears more effective than adjuvant therapy because it leverages the in-situ tumor and its associated lymph nodes as a 'training ground.' This allows the immune system to generate a robust, specific anti-tumor response before the primary tumor and nodal basin are surgically removed.

A powerful analogy for combination immunotherapy: PD-1 checkpoint inhibitors act like releasing the brake on the immune system, reactivating existing but exhausted T-cells. In contrast, a cancer vaccine like NUS209 is the accelerator, creating entirely new T-cells and reactivities that can target the tumor, providing a synergistic effect.